Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation
March 18, 2026 |
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
Lucid’s US Medical Affairs division unveils new proprietary insights tools to expand advisory capabilities.
LONDON & PHILADELPHIA, March 18, 2026 – Lucid Group, a global leader in healthcare communications and commercialisation, today announced that Rod MacKenzie, CMG, PhD, former Executive Vice President and Chief Development Officer at Pfizer, has been appointed as the new Chair of the Lucid Group Board of Directors. Dr MacKenzie will succeed Andy Black, who retired from the Board following the end of his term.
This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn’t stop at approval but reaches the patients who need it most. His leadership marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
“Dr MacKenzie’s career is defined by his dedication to patient outcomes and a deep understanding that breakthrough science only matters when translated into action,” said Rick Sannem, CEO of Lucid Group. “His arrival supports our shared vision that we don’t just help clients talk about their science, we uncover the defining insights that shape behaviour so life-changing medicines find their rightful place in the market.”
Dr MacKenzie spent 34 years at Pfizer, where he led the Global Product Development division and oversaw 6,000 professionals dedicated to advancing innovative medicines and vaccines. He played a critical role in the development of both the Pfizer-BioNTech COVID-19 vaccine and antiviral, Paxlovid, in addition to serving on Pfizer’s Executive Leadership Team from 2016 to 2022. In recognition of his contributions to public health during the pandemic, he was appointed Companion of the Order of St Michael and St George by Queen Elizabeth II in 2022.
“Inventing and developing innovative medicines takes great science and execution. But translating that science into improved patient outcomes in clinical practice requires real strategic discipline,” said Dr MacKenzie. “Even brilliant science can struggle to break through, so innovative companies need a strategic partner like Lucid, whose integrated approach to solving complex challenges delivers changes in behaviours that successfully overcome treatment barriers. Lucid’s cre
ativity and unique data synthesis capabilities really stand out in the marketplace. I am thrilled to join the Lucid Board and share Lucid’s deep commitment to transforming lives across the globe.”
In addition to Dr MacKenzie’s appointment, Lucid’s US Medical Affairs division is unveiling new proprietary insights tools to expand its advisory capabilities at the Medical Affairs Professional Society (MAPS) conference in Denver from 22-25 March:
- Influence Amplifier™ – Closes the gap between communication and behaviour change by combining real-time behavioural insights, precision targeting, and adaptive analytics to expand peer-to-peer communication relevance and audience priorities.
- Impact Validator™ – Pinpoints precisely where efforts drive change through a five-step framework spanning clinical gaps and audience priorities, tailored interventions, omnichannel engagement, performance data, and adaptive refinement.
Together, these tools magnify and document scientific impact while delivering Precision Engagement™, a repeatable, self‑optimising cycle that continuously strengthens scientific influence, impact, and patient outcomes over time.
To demonstrate how Lucid Medical is enabling Medical Affairs teams to be strategic catalysts for change, it is offering free, 30-minute Impact Calibration™ sessions designed to map Medical Affairs teams’ current influence and spotlight opportunities for measurable growth.
About Lucid Group
Lucid Group, a global leader in healthcare communications and commercialisation, is driven by a mission to transform lives by bridging the gap between scientific discovery and patient impact. For life sciences organisations navigating their highest-stakes decisions, Lucid doesn’t just communicate science but ensures clients leave a lasting impact on the market and the patients they serve. Lucid brings together experts across Strategy Consulting, Scientific and Medical Communications, and Commercial Communications, fusing scientific rigour, strategic foresight, commercial ingenuity, creative storytelling, and deep human insight into an integrated force, powered by real-world evidence. This unique approach allows Lucid to uncover the ‘Lucid Truth’— the deep-seated insight that governs stakeholder behaviour and anchors bold, behaviour-changing ideas, executed at key moments and accelerated by AI and technology. To learn more about Lucid Group, visit www.wearelucidgroup.com and LinkedIn.
Media Contacts:
Chris Dougherty
CDougherty@reboundb2b.com
Elyse Cole
media@wearelucidgroup.com
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
A dynamic and challenging environment – what it’s like starting a career in MedComms
Ayala Donegan discusses her #LucidLife journey into #MedComms
A Magical Future – A year on from the graduate scheme
Emilie discusses her #LucidLife journey during the past year, after joining Lucid through their graduate scheme.The summer after I graduated from university, I spent a lot of time trying to...
Lucid kick-starts 2019 with spellbinding new additions to its writing and account teams
It’s been a busy start to 2019, with Lucid Group bolstering its account and medical writing teams with three new additions.Elaine Downey joins Vivid as a Senior Account Manager; she...
Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
Lucid Group is setting itself up for another stellar year with a new appointment to their senior leadership team. Rob Apollo has joined Lucid on a permanent basis as Director...
Lucid Group welcomes new talent into their 2019 Futures Academy
Lucid welcomed six new graduates into their training programme, The Futures Academy, this week. Launched in 2017, the Futures Academy is now a well-oiled machine, training and developing new talent...
Lucid Winter Meeting 2018
The teams gathered at The Artisan in Clerkenwell, London, to reflect on the year and celebrate both team and individual contributions to Lucid, their clients and the local community through...
2018 was a magical year for Lucid Group, filled with memorable moments and many celebrations
This year has been a ground-breaking year for Lucid Group, punctuated by magical makeovers, plenty of awards, landmark staff celebrations and worthwhile charity work.The tone of the year was set...
Lucid Group celebrate another magical year at their Winter Meeting
2018 has without doubt been a stellar year for Lucid Group, scooping a double win at Communiqué - winning both Communiqué Medical Education Consultancy of the Year and Communiqué Communications...
Lucid Group welcomes new magical talent and boosts their medical writing teams with hires in the US and UK
Lucid group welcomes four new additions to their medical writing family, with new hires across the UK and USA.Sonal Adhav joins Lighthouse Medical Communications US as a Senior Scientific Director...
Lucid attend the Wycombe BIG SLEEPOUT in aid of Wycombe Homeless Connection
The inside story from the Big Sleepout on Saturday, 24 November in support of Lucid's charity partner the Wycombe Homeless Connection.